Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?

International journal of geriatric psychiatry - 1 Jun 2009

Wallin A K, Hansson O, Blennow K, Londos E, Minthon L

Abstract excerpt

OBJECTIVE: The main objective of this study was to investigate possible predictors of response to cholinesterase inhibitor (ChEI) treatment, including pre-treatment progression rates and levels of the cerebrospinal fluid (CSF) biomarkers. A secondary objective was to evaluate whether treatment with ChEI changed progression. METHODS: Out-patient individuals (n = 191) with the clinical diagnosis of Alzheimer's...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid beta-Peptides
Share to Apolipoprotein E4

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholinesterase Inhibitors

Share to Geriatric Assessment

Share to Peptide Fragments

Share to Psychological Tests

Share to Sweden

Share to tau Proteins

Source

Identifiers

PMID: 19123199
DOI: 10.1002/gps.2195

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?PMID 19123199Read ↗

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.Semantic proximity Read ↗

Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease.Semantic proximity Read ↗

Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype.Semantic proximity Read ↗

An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM.Semantic proximity Read ↗

An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative.Semantic proximity Read ↗

Development of a prediction model of conversion to Alzheimer’s disease in subjects with mild cognitive impairment: the statistical analysis plan of the INTERCEPTOR projectSemantic proximity Read ↗

Effectiveness of Nootropics in Combination with Cholinesterase Inhibitors on Cognitive Function in Mild-to-Moderate Dementia: A Study Using Real-world DataSemantic proximity Read ↗

Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.Semantic proximity Read ↗

Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.Semantic proximity Read ↗

Effects of time and cholinesterase inhibitor treatment on multiple cerebrospinal fluid parameters in Alzheimer's disease.Semantic proximity Read ↗

Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.